MX339253B - Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile. - Google Patents

Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.

Info

Publication number
MX339253B
MX339253B MX2012011926A MX2012011926A MX339253B MX 339253 B MX339253 B MX 339253B MX 2012011926 A MX2012011926 A MX 2012011926A MX 2012011926 A MX2012011926 A MX 2012011926A MX 339253 B MX339253 B MX 339253B
Authority
MX
Mexico
Prior art keywords
antibodies
clostridium difficile
disease
treatment
compositions
Prior art date
Application number
MX2012011926A
Other languages
English (en)
Other versions
MX2012011926A (es
Inventor
Naoya Tsurushita
Shankar Kumar
Dangshe Ma
Kirsten Nagashima
Brian Kennedy
Gerald P Donovan
Yun Kang
William C Olson
Andre J Marozsan
Albert Cupo
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of MX2012011926A publication Critical patent/MX2012011926A/es
Publication of MX339253B publication Critical patent/MX339253B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a reactivos, composiciones, y terapias con las cuales se tratan condiciones y patologías de infección por y enfermedad relacionada con Clostridium difficíle, tal como diarrea asociada con Clostridium difficile, que resulta de la infección por bacterias Clostridium difficile y las enterotoxinas producidas por estas bacterias. En particular, se proporcionan anticuerpos o fragmentos de unión a antígeno de los mimos que se unen específicamente a toxina A y/o toxina B de C. difficile y neutralizan las actividades de estas toxinas, composiciones que comprenden dichos anticuerpos; y métodos para utilizar los anticuerpos y las composiciones.
MX2012011926A 2010-04-15 2011-04-15 Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile. MX339253B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32450310P 2010-04-15 2010-04-15
US38166910P 2010-09-10 2010-09-10
PCT/US2011/032713 WO2011130650A2 (en) 2010-04-15 2011-04-15 Antibodies for the treatment of clostridium difficile-associated infection and disease

Publications (2)

Publication Number Publication Date
MX2012011926A MX2012011926A (es) 2013-01-29
MX339253B true MX339253B (es) 2016-05-18

Family

ID=44799348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011926A MX339253B (es) 2010-04-15 2011-04-15 Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.

Country Status (11)

Country Link
US (2) US8986697B2 (es)
EP (1) EP2558493B1 (es)
JP (2) JP5965389B2 (es)
KR (1) KR101820987B1 (es)
CN (1) CN102947334B (es)
AU (1) AU2011239470B2 (es)
BR (1) BR112012026021B1 (es)
CA (1) CA2795953C (es)
ES (1) ES2757675T3 (es)
MX (1) MX339253B (es)
WO (1) WO2011130650A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
LT2753352T (lt) 2010-09-03 2017-05-25 Valneva Austria Gmbh Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
SG10201804809RA (en) 2011-08-22 2018-07-30 Cnj Holdings Inc Clostridium difficile antibodies
SI2758432T1 (sl) * 2011-09-16 2019-07-31 Ucb Biopharma Sprl Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
JP6084631B2 (ja) * 2011-12-08 2017-02-22 ノバルティス アーゲー Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
CN102590515B (zh) * 2012-01-13 2014-07-30 张春华 艰难梭菌外毒素a检测试剂盒及组成该试剂盒的单克隆抗体
US9579354B2 (en) 2012-01-23 2017-02-28 Santalis Pharmaceuticals, Inc. Sandalwood oil and its uses related to clostridium infections
TWI592422B (zh) * 2012-03-02 2017-07-21 再生元醫藥公司 抗艱難梭狀芽孢桿菌毒素之人類抗體
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
US20150259402A1 (en) 2012-10-19 2015-09-17 Evec Inc. Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
CN105025926B (zh) * 2012-11-28 2018-12-14 Cnj控股公司 针对艰难梭菌的抗体
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
CA2909636C (en) * 2013-04-19 2023-08-22 Dena Lyras Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
EP2988778A4 (en) * 2013-04-22 2016-12-14 Board Of Regents Of The Univ Of Oklahoma CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP3277706A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
AU2016248128A1 (en) * 2015-04-15 2017-10-19 Medimmune, Llc Methods for treating Clostridium difficile infection and associated disease
GB201509326D0 (en) * 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
AU2017238644B2 (en) * 2016-03-24 2022-12-15 Paratek Pharmaceuticals, Inc. Methods for treating and preventing C. difficile infection
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20190359695A1 (en) * 2017-02-10 2019-11-28 Stc.Unm Recombinant expression systems and products
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
GB201807367D0 (en) * 2018-05-04 2018-06-20 Univ Newcastle Biomarker
RU2694549C1 (ru) * 2018-08-16 2019-07-16 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ здоровья детей" Минздрава России) Способ ведения детей с болезнью Гиршпрунга в периоперационном периоде
WO2021219786A1 (en) 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US6071517A (en) 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2006121422A2 (en) * 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
CA2592015A1 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP2033657A1 (de) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease

Also Published As

Publication number Publication date
KR101820987B1 (ko) 2018-01-22
JP6159854B2 (ja) 2017-07-05
WO2011130650A2 (en) 2011-10-20
US8986697B2 (en) 2015-03-24
MX2012011926A (es) 2013-01-29
JP2017012166A (ja) 2017-01-19
US20150175681A1 (en) 2015-06-25
US20130202618A1 (en) 2013-08-08
AU2011239470A1 (en) 2012-11-01
JP2013523190A (ja) 2013-06-17
EP2558493B1 (en) 2019-09-18
CN102947334B (zh) 2017-12-26
CA2795953C (en) 2021-09-14
KR20130062279A (ko) 2013-06-12
JP5965389B2 (ja) 2016-08-03
BR112012026021B1 (pt) 2022-05-03
AU2011239470B2 (en) 2015-09-10
CA2795953A1 (en) 2011-10-20
ES2757675T3 (es) 2020-04-29
BR112012026021A2 (pt) 2020-04-14
CN102947334A (zh) 2013-02-27
WO2011130650A3 (en) 2012-04-12
EP2558493A4 (en) 2013-11-27
EP2558493A2 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
MX2012011926A (es) Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
EP3470526A3 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012047427A3 (en) Antibodies for botulinum neurotoxins
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
MX2019000046A (es) Anticuerpos anti-il-23.
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
NZ714516A (en) Human antibodies to clostridium difficile toxins
MX347164B (es) Anticuerpos anti-il-36r.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
MX2013009362A (es) Anticuerpo contra el csf-1r.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2013009151A (es) Inmunoterapia mejorada.
SG10201804809RA (en) Clostridium difficile antibodies
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2010014854A3 (en) Antibodies that neutralize botulinum neurotoxins
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2009008916A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2013006449A3 (en) Anti-properdin antibodies and uses thereof
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration